GTC BIOTHERAPEUTICS TO HOST THIRD QUARTER 2005 EARNINGS CALL AND WEBCAST ON WEDNESDAY, NOVEMBER 2, 2005 CORPORATE PRESENTATION TO BE WEBCAST FROM THREE INVESTOR CONFERENCES Framingham, Mass., October 26, 2005-- GTC Biotherapeutics, Inc. (Nasdaq: GTCB) ("GTC") announced today that its financial results for the third quarter 2005 will be released on Wednesday, November 2, 2005 before the Nasdaq market opens. Geoffrey F. Cox, Ph.D., Chairman of the Board, Chief Executive Officer and President, will lead the call on November 2 starting at 10:00 a.m. Eastern Time to discuss these results and the Company's drug development progress. You may access the live internet broadcast or the subsequent archived recording, on GTC's website at http://www.gtc-bio.com or as follows: Live Call - In the United States, dial 1-800-591-6942 Outside the United States, dial 1-617-614-4909 Reference call ID: when prompted 28919663 Audio Archive - In the United States, dial 1-888-286-8010 Outside the United States, dial 1-617-801-6888 Reference call ID: when prompted 52115376 NOTE: a replay of the call will be available one hour following the end of the call and will be accessible until November 9, 2005. The earnings webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.earnings.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com). CORPORATE PRESENTATION WEBCASTS Geoffrey Cox, Ph.D., is also scheduled to present an update on GTC's product and corporate development at three upcoming investor conferences: 7th Annual MassOpps Investor Conference, Logan Airport Hilton, Boston, MA November 3 at 4:00 pm ET. Rodman & Renshaw 7th Annual Healthcare Conference, New York Palace Hotel, New York, NY November 7 at 12:20 pm ET. SG Cowen & Co. 6th Annual Global Health Care Conference, Hilton Diagonal Mar, Barcelona, Spain November 10 at 10:20 am ET. All three presentations will be webcast live and can be accessed by logging onto www.gtc-bio.com. The replays can be accessed from this same website and will be available within 24 hours of the presentation. GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC currently has five products in its internal pipeline and a portfolio of external program production opportunities. GTC's lead program is ATrynŽ, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATrynŽ in patients with a hereditary antithrombin deficiency. In addition to the lead ATrynŽ program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. Additional information is available on the GTC web site, http://www.gtc-bio.com. CONTACT: GTC Biotherapeutics Thomas E. Newberry Vice President, Corporate Communications (508) 370-5374 Feinstein Kean Healthcare Francesca DeVellis (investors) (617) 577-8110 Back to 2005 Archives
	Copyright 2006 GTC Biotherapeutics, All Rights Reserved